Research Article Volume 8 • Issue 5 343 Dihydrogen inhalation in the Management of Patients with Moderate Oxygen-Requiring COVID19: Towards an Innovative Therapy Cordélia Salomez-Ihl 1,2* , Joris Giai 3 , Mathieu Roustit 3 , François Boucher 1 , Philippe Cinquin 1,3 , Jean-Paul Brion 4 Abstract The Coronavirus Disease 2019 (Covid-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has resulted in a substantial global health crisis, with millions of deaths reported since its initial discovery in China in November 2019. The global variability in immunization access underscores the critical necessity for ongoing research into therapeutic strategies. This study explores the application of molecular dihydrogen (H 2 ) inhalation as a potential adjuvant treatment for Covid-19. H 2 therapy has shown promise in inhibiting inflammation-related intracellular signaling pathways, particularly when administered early in conjunction with nasal oxygen therapy. Presented here are two cases from an ongoing phase one study evaluating the safety and Dose Limiting Toxicity (DLT) of H 2 therapy delivered via a nasal cannula in addition to conventional oxygen therapy for Covid-19 patients requiring nasal oxygen (1 to 6 L/min). Tolerance was excellent in both cases, with no adverse events attributed to H 2 reported. Patient 1, a 56-year-old man, and Patient 2, a 59-year-old woman, exhibited positive responses to the H 2 therapy, demonstrating improvements of O 2 saturation and a decrease in C-Reactive Protein (CRP) levels. The gas mixture's safety and efficacy were supported by clinical and biological observations, aligning with existing literature on H 2 's anti-inflammatory effects. This preliminary study suggests that inhaled H 2 , administered alongside oxygen therapy, may expedite the clinical improvement of pulmonary SARS-CoV-2 disease, potentially preventing Intensive Care Unit (ICU) transfers. The positive outcomes observed in these cases warrant further investigation in larger, controlled clinical trials. Affiliation: 1 Université Grenoble Alpes, CNRS, UMR 5525, VetAgro Sup, Grenoble INP, CHU Grenoble Alpes, TIMC, UMR5525, 38000 Grenoble, France 2 Université Grenoble Alpes, CHU Grenoble Alpes, Department of Pharmacy, 38000 Grenoble, France 3 Université Grenoble Alpes, Inserm, CHU Grenoble Alpes, CIC1406, 38000 Grenoble, France 4 CHU Grenoble Alpes, Department of Infectious and Tropical Diseases, 38000 Grenoble, France *Corresponding author: Cordélia Salomez-Ihl, Université Grenoble Alpes, CNRS, UMR 5525, VetAgro Sup, Grenoble INP, CHU Grenoble Alpes, TIMC, UMR5525, 38000 Grenoble, France. Citation: Cordélia Salomez-Ihl, Joris Giai, Mathieu Roustit, François Boucher, Philippe Cinquin, Jean-Paul Brion. Dihydrogen inhalation in the Management of Patients with Moderate Oxygen- Requiring COVID19: Towards an Innovative Therapy. Archives of Clinical and Biomedical Research. 8 (2024): 343-346. Received: June 14, 2024 Accepted: June 20, 2024 Published: September 05, 2024 Keywords: COVID 19; Anti-inflammatory Agents; Non-Steroidal; Inhalation Key Clinical Message: Dihydrogen (H 2 ) inhalation has shown promising results as a treatment for two hospitalized patients with moderate COVID 19. Introduction Coronavirus Disease 2019 (Covid-19), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has led to millions of deaths since its discovery in China in November 2019 [1]. The primary manifestation is severe and potentially fatal lung damage, often associated